List of Excipients in Branded Drug ZEGALOGUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	ZEGALOGUE	dasiglucagon	0169-1913	HYDROCHLORIC ACID	2026-03-22
Novo Nordisk	ZEGALOGUE	dasiglucagon	0169-1913	SODIUM CHLORIDE	2026-03-22
Novo Nordisk	ZEGALOGUE	dasiglucagon	0169-1913	SODIUM HYDROXIDE	2026-03-22

Zegalogue Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Zegalogue, Zealand Pharma’s dasiglucagon injection, uses a deliberately simple, preservative-free liquid formulation. The product’s commercial value comes less from excipient complexity than from ready-to-use delivery, room-temperature handling for limited periods, and compatibility with prefilled syringe and autoinjector presentations. The strongest formulation opportunities are improved temperature stability, lower injection volume, longer shelf life, and differentiated rescue formats for mini-dose use and automated insulin-delivery systems.

What is Zegalogue and how is it formulated?

Zegalogue is a glucagon analog approved for the treatment of severe hypoglycemia in adults and children aged 6 years and older with diabetes. Each single-dose presentation contains 0.6 mg dasiglucagon in 0.6 mL of solution, corresponding to a concentration of 1 mg/mL [1].

Zegalogue formulation composition

Component	Function	Commercial relevance
Dasiglucagon hydrochloride	Active pharmaceutical ingredient	Stable glucagon-receptor agonist intended to raise blood glucose
Glycerol	Tonicity agent and formulation stabilizer	Supports injectable comfort and solution properties
Hydrochloric acid	pH adjustment	Establishes the required acidic formulation environment
Sodium hydroxide	pH adjustment	Fine-tunes formulation pH
Water for Injection	Vehicle	Standard parenteral solvent

The formulation does not use a preservative, surfactant, buffer system, or lyophilization step according to the U.S. prescribing information [1]. The low excipient count reduces manufacturing complexity and limits potential excipient-related tolerability issues.

Zegalogue is supplied as a single-dose prefilled syringe and a single-dose autoinjector. The formulation is intended for direct administration without reconstitution or dose preparation [1].

Why is the Zegalogue excipient strategy commercially important?

The formulation supports a rescue product that can be administered rapidly by nonprofessionals. This differentiates Zegalogue from conventional emergency glucagon kits that historically required powder reconstitution before injection.

The primary commercial benefits are:

1. Immediate readiness for use.
2. Lower handling burden for caregivers, schools, and emergency responders.
3. Reduced risk of preparation errors.
4. Compatibility with compact prefilled delivery systems.
5. A simplified manufacturing process compared with lyophilized glucagon kits.

The tradeoff is that liquid peptide formulations require strong control of chemical and physical stability. Dasiglucagon must remain soluble and potent during refrigerated storage, transport, device residence, and limited room-temperature exposure.

What storage and temperature requirements affect Zegalogue commercialization?

Zegalogue must be stored refrigerated at 2°C to 8°C. The product may be stored at temperatures up to 30°C for a limited period of 28 days, after which it must be discarded even if returned to refrigeration [1].

This creates a mixed commercial profile.

Commercial advantages

The 28-day room-temperature allowance supports:

• Home storage during short travel periods.
• Emergency kits kept outside a refrigerator for limited periods.
• School and workplace stocking.
• Reduced concern during short shipping interruptions.
• Distribution into markets with constrained cold-chain infrastructure.

Commercial limitations

The product is not a fully room-temperature-stable rescue medicine. The label’s temperature restriction creates exposure to:

• Product loss from prolonged heat exposure.
• Retail and pharmacy inventory controls.
• Patient confusion about when the 28-day period begins.
• Higher distribution costs in hot climates.
• Potential replacement demand after storage excursions.

An excipient or container-closure improvement that extended room-temperature stability from 28 days to 60 or 90 days could provide a commercially meaningful distinction, particularly in retail, school, military, travel, and emerging-market channels.

Which excipients are most important for Zegalogue?

Glycerol

Glycerol is the principal functional excipient disclosed in the commercial formulation. Its likely roles include tonicity adjustment and support of protein or peptide solution stability. The excipient is widely used in parenteral products and has a long regulatory history.

Glycerol creates a relatively low regulatory barrier because it is a familiar injectable excipient. Its strategic value lies in enabling a liquid product without adding a more complex buffer or surfactant system.

Potential development constraints include:

• Osmolality control.
• Viscosity at the selected concentration.
• Compatibility with autoinjector needle systems.
• Effects on injection force and delivery time.
• Interaction with container materials and silicone oil.

A future formulation using a different polyol, amino acid, or stabilizing excipient could be patentable if it provides a demonstrated improvement in potency retention, aggregation control, or temperature stability.

Hydrochloric acid and sodium hydroxide

These ingredients are pH adjusters rather than primary formulation differentiators. Their presence indicates that the formulation pH is controlled through acid-base adjustment rather than a disclosed buffered system.

That approach reduces excipient load but places greater pressure on:

• pH control during manufacturing.
• Long-term pH drift.
• Container-closure interaction.
• Chemical degradation pathways.
• Stability after device filling.

A formulation patent based only on routine pH adjustment would generally face a higher obviousness risk. Stronger protection would require a defined pH range linked to unexpected stability or delivery performance.

Water for Injection

Water for Injection is the standard vehicle for parenteral administration. It does not create meaningful commercial differentiation, but it imposes conventional requirements for sterility, endotoxin control, particulate control, and container-closure integrity.

What formulation patents could protect Zegalogue or next-generation dasiglucagon products?

The most defensible formulation patent opportunities would relate to measurable performance improvements rather than the basic use of glycerol, water, acid, or base.

Potential formulation patent areas

Opportunity	Technical objective	Commercial value
Room-temperature-stable liquid formulation	Extend stability beyond the current 28-day allowance	Lower replacement rates and expand geographic distribution
Low-volume formulation	Deliver the same dose in less than 0.6 mL	Improve autoinjector ergonomics and reduce injection burden
High-concentration formulation	Preserve potency at increased drug concentration	Enable smaller devices and alternate rescue formats
Surfactant-free stabilization	Control aggregation without polysorbates or related agents	Reduce oxidation, leachables, and immunogenicity concerns
Container-closure optimization	Reduce adsorption, silicone interaction, or extractables	Improve shelf life and device reliability
Multidose formulation	Support repeated dosing from a single device	Enable mini-dose and chronic-use applications
Freeze-thaw-resistant formulation	Protect product during transport excursions	Reduce cold-chain losses
Alternative pH system	Improve chemical stability or injection tolerability	Support lifecycle management and patent differentiation

A formulation patent would be strongest when it claims a defined composition linked to comparative data, such as improved potency after accelerated storage, lower aggregate content, or better delivery performance through the commercial device.

How does Zegalogue compare with conventional glucagon products?

Attribute	Zegalogue	Conventional emergency glucagon kits
Active ingredient	Dasiglucagon	Glucagon
Presentation	Ready-to-use liquid	Frequently lyophilized powder requiring reconstitution
Dose preparation	None	Mixing and transfer may be required
Delivery	Prefilled syringe or autoinjector	Vial and syringe or newer ready-to-use formats
Preservative strategy	Preservative-free single dose	Product-specific
Storage	Refrigerated, with limited room-temperature allowance	Product-specific
User burden	Lower	Historically higher
Formulation complexity	Low excipient count, liquid	Lyophilized or liquid depending on product
Main differentiation	Ready-to-use dasiglucagon delivery	Established glucagon familiarity and broader legacy use

The competitive set includes Xeris Pharmaceuticals’ Gvoke, a ready-to-use liquid glucagon product, and newer nasal glucagon products such as Baqsimi. These products compete on usability, storage, device design, onset, caregiver acceptance, and reimbursement rather than on active ingredient alone.

What commercial opportunities exist for Zegalogue excipient innovation?

School and caregiver rescue kits

The strongest near-term opportunity is improving storage robustness. Schools and caregivers often need products that remain reliable in uncontrolled environments. A formulation with longer room-temperature stability could reduce product replacement and improve stocking compliance.

A secondary opportunity is a compact, low-force autoinjector that uses a more concentrated formulation. This would support smaller emergency kits and easier handling by children’s caregivers.

Mini-dose glucagon

Mini-dose glucagon is used in some diabetes-management settings to treat impending or mild hypoglycemia without delivering a full emergency dose. Dasiglucagon’s liquid presentation is technically suited to this concept, but the commercial product and labeling must support the intended dosing method.

Potential product formats include:

• A multidose pen.
• A cartridge-based delivery system.
• A metered-dose autoinjector.
• A low-dose prefilled syringe.
• A digital dosing aid linked to an insulin-management application.

These uses would likely require new clinical evidence, dose accuracy validation, device development, and regulatory submissions. They also create an opportunity for formulation work focused on repeated puncture, multidose antimicrobial control, and extended in-use stability.

Automated insulin-delivery systems

Dasiglucagon has potential as a rescue or counter-regulatory component in dual-hormone artificial-pancreas systems. In that setting, the formulation must satisfy more demanding requirements than a single emergency injection.

Key technical requirements include:

• Long-term stability in a pump reservoir.
• Compatibility with pump tubing and reservoir materials.
• Low adsorption to device surfaces.
• Resistance to aggregation under agitation.
• Reliable delivery at very low flow rates.
• Minimal clogging or particulate formation.
• Multi-day in-use stability at body-adjacent temperatures.

A pump-compatible formulation could support licensing to diabetes-device companies and create a new market beyond emergency rescue products.

Global and hot-climate markets

The current storage profile may limit penetration in regions with unreliable refrigeration or high ambient temperatures. A heat-stable formulation could support:

• Public-sector diabetes programs.
• Humanitarian supply chains.
• Military and remote-workplace kits.
• Pharmacies without continuous refrigeration.
• Distribution in tropical regions.

The commercial value would depend on whether improved stability can be achieved without raising viscosity, altering injection force, or introducing excipients that complicate global regulatory review.

What regulatory issues affect excipient changes?

Zegalogue was approved by the FDA as a drug product under the New Drug Application pathway, not as a biosimilar [2]. Dasiglucagon is a peptide analog, and future competitors would likely assess an abbreviated new drug application or a 505(b)(2) pathway depending on the proposed active ingredient, formulation, device, and clinical claims.

An excipient change could trigger:

• Comparative stability studies.
• New extractables and leachables work.
• Device compatibility testing.
• Container-closure integrity studies.
• Updated particulate and sterility data.
• Human-factors testing.
• Bridging pharmacokinetic or pharmacodynamic studies.
• New clinical data if exposure or safety could change.

For an ANDA or 505(b)(2) competitor, the formulation and device can create meaningful barriers even if the active peptide is chemically similar. A different excipient system may require additional regulatory justification, especially where it changes absorption, injection tolerability, viscosity, or product stability.

Does Zegalogue have biosimilar risk?

Zegalogue does not face conventional biosimilar risk in the same way as a monoclonal antibody or other licensed biologic. The principal competitive risk is from generic, hybrid, or alternative glucagon products, depending on the legal and regulatory pathway available for the proposed product.

The practical risk has several layers:

1. Active-ingredient replication.
2. Formulation similarity.
3. Device substitution.
4. Orange Book patent and exclusivity analysis.
5. Human-factors equivalence.
6. Reimbursement and pharmacy substitution.

A competitor that matches the active ingredient but uses a different delivery system may compete through a 505(b)(2) application rather than a straightforward ANDA. A competitor that offers a ready-to-use glucagon product with a different active ingredient can avoid direct formulation copying and compete through clinical usability.

What is the FDA exclusivity and patent position for Zegalogue?

The FDA approved Zegalogue in March 2021 for severe hypoglycemia in adults and pediatric patients aged 6 years and older [2]. The approval was based on studies showing rapid increases in plasma glucose after administration.

The product’s regulatory protection is separate from patent protection. FDA approval alone does not establish the complete patent term, Orange Book listing status, or timing of potential generic entry. Those issues depend on the current FDA Orange Book, patent listings, patent-term adjustments, pediatric exclusivity, litigation, and any settlement agreements.

The most commercially relevant legal assets are likely to include:

• Dasiglucagon composition claims.
• Injectable formulation claims.
• Stable liquid formulation claims.
• Prefilled-device claims.
• Autoinjector or syringe presentation claims.
• Methods for treating severe hypoglycemia.
• Pump or artificial-pancreas applications.

Method-of-use patents may remain relevant even where formulation claims are challenged. Device and formulation patents can also delay practical substitution if a competitor cannot provide an equivalent ready-to-use presentation.

No broad conclusion about generic launch timing should be drawn solely from the FDA approval date.

Which companies challenge or compete with Zegalogue?

The competitive landscape includes both direct glucagon competitors and substitute rescue technologies.

Company	Product or platform	Competitive relevance
Zealand Pharma	Zegalogue, dasiglucagon	Ready-to-use injectable glucagon analog
Xeris Pharmaceuticals	Gvoke	Ready-to-use liquid glucagon
Eli Lilly	Baqsimi	Nasal glucagon rescue product
Novo Nordisk	GlucaGen and related glucagon products	Established injectable glucagon franchise
Insulet and other pump companies	Automated insulin-delivery systems	Potential users of stable glucagon formulations
Academic and development-stage groups	Dual-hormone pump and mini-dose systems	Potential future demand for pump-compatible dasiglucagon

The commercial competition is based on ease of use, device reliability, storage requirements, reimbursement, caregiver confidence, and access through pharmacies and diabetes clinics.

How strong is the Zegalogue excipient strategy?

The current strategy is strong for initial commercialization but less differentiated for long-term lifecycle protection.

Strengths

• Simple, low-burden excipient system.
• Preservative-free single-dose presentation.
• Ready-to-use liquid format.
• Compatibility with prefilled syringe and autoinjector delivery.
• Lower preparation burden than reconstituted glucagon.
• Familiar excipients with established regulatory use.

Weaknesses

• Glycerol, water, acid, and base offer limited standalone patent differentiation.
• Refrigerated storage remains necessary.
• Room-temperature stability is limited to 28 days.
• A liquid peptide product must manage aggregation, adsorption, and device interaction.
• Competing products can differentiate through nasal delivery or alternative liquid formulations.
• The current product is not optimized for multidose or pump use.

The strongest lifecycle strategy would combine formulation improvement with device, method-of-use, and manufacturing claims.

What manufacturing and intellectual-property barriers affect expansion?

A next-generation product must solve several manufacturing problems:

• Consistent peptide purity and impurity control.
• Low bioburden and endotoxin levels.
• Aseptic filling into low-volume primary containers.
• Control of subvisible particles.
• Compatibility with autoinjector components.
• Container-closure integrity over shelf life.
• Resistance to freezing and temperature excursions.
• Reproducible injection force.

The manufacturing process itself may offer patent opportunities around purification, crystallization, peptide handling, or control of degradation products. These claims could supplement formulation patents but would not necessarily prevent a competitor from manufacturing the same active ingredient through a different process.

Key Takeaways

• Zegalogue uses a simple preservative-free liquid formulation containing dasiglucagon, glycerol, hydrochloric acid, sodium hydroxide, and Water for Injection.
• The excipient strategy supports ready-to-use administration but provides limited standalone differentiation.
• The principal commercial formulation opportunity is extending room-temperature stability beyond the current 28-day allowance.
• Other opportunities include higher concentration, lower injection volume, multidose delivery, mini-dose glucagon, and pump-compatible formulations.
• Zegalogue competes with Gvoke, Baqsimi, legacy glucagon kits, and future dual-hormone diabetes devices.
• Dasiglucagon is not exposed to conventional biosimilar competition; generic, hybrid, device-based, and alternative-product competition are more relevant.
• Formulation, container-closure, device, manufacturing, and method-of-use patents could provide stronger lifecycle protection than basic excipient claims.
• The most valuable future product would combine heat stability, low-volume delivery, reliable device performance, and compatibility with automated insulin-delivery systems.

FAQs

Can Zegalogue be reformulated without glycerol?

Yes, but a replacement would need to preserve tonicity, peptide stability, injection performance, and container compatibility. A successful substitute could support a new formulation patent if it provides a measurable advantage.

Is Zegalogue preservative-free?

Yes. The labeled single-dose formulation does not disclose a preservative [1]. The single-use presentation avoids the need for multidose antimicrobial preservation.

Could a room-temperature Zegalogue product replace the current formulation?

A room-temperature-stable product could improve distribution and reduce product wastage, but it would require a new stability package, container-closure assessment, device studies, and potentially additional regulatory review.

Does a Zegalogue generic need to copy the autoinjector?

Not necessarily. A competing product could pursue a different device or regulatory pathway, but the alternative presentation would need to meet applicable requirements for dose delivery, usability, labeling, and substitutability.

Could dasiglucagon be used in an artificial pancreas?

Potentially. Its use in an automated insulin-delivery system would require a formulation and device system with demonstrated stability, low adsorption, reliable low-flow delivery, and appropriate clinical and regulatory validation.

References

1. U.S. Food and Drug Administration. (2024). Zegalogue (dasiglucagon) injection, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2021, March 22). FDA approves first ready-to-use glucagon treatment for severe hypoglycemia. FDA.

3. Zealand Pharma A/S. (2024). Annual report 2023. Zealand Pharma.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.